COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

September 10, 2018 - October 26, 2018

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES	ID	20				**20**
	MEDICAL MICROBIOLOGY	MM	10		2 X 1=2 (4 Groups)		**12**
	PHARMACOLOGY	PC	21				**21**
	PATHOLOGY	PT	12			2	**14**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	12				**12**
	HEMATOLOGY	HEM	11				**11**
	PUBLIC HEALTH	PH	8				**8**
	IMMUNOLOGY	IMM	6				**6**
	MEDICAL GENETICS	MG	5				**5**
	PEDIATRICS	PED	5				**5**
	PATHOPHYSIOLOGY	PP	4				**4**
	PHYTOTHERAPY	PHY	3				**3**
	BIOSTATISTICS	BS	3				**3**
	ONCOLOGY	ONC	3				**3**
	FAMILY MEDICINE	FM	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	SCIENTIFIC PROJECTS-III	SP				2	**2**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2 X 3=6 (4 Groups)		**6**
TOTAL			**125**		**8**	**6**	**139**

Coordination Committee

HEAD	Meral Sönmezoğlu, MD, Prof.
SECRETARY	Atilla Özkan, MD, Assoc. Prof
MEMBER	Hülya Sarıçoban, MD, Assoc. Prof.
MEMBER	Mustafa Ferudun Çelikmen, MD, Asst Prof.
MEMBER	Ayşegül Kuşkucu, MD, Asst. Prof.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof. Çağrı Büke, MD, Prof.
MEDICAL MICROBIOLOGY	İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Asst. Prof
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof Hülya Sarıçoban, MD, Assoc. Prof. S.Perihan Saf, MD
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Asst. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, Assoc. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
ONCOLOGY	Okan Kuzhan, MD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Asst. Prof. Pınar Tura, MD, Asst. Prof. Vildan Öztürk, MD, Asst. Prof. Rasim Yılmazer, MD, Asst. Prof. Serdar Özdemir, MD, Asst. Prof. Mustafa Yazıcıoğlu, MD. Cem Şimşek, MD.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

INFECTIOUS DISEASES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2.1. ***recall*** structures, and
2.2. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3.0. ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,

4.0. ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0. ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0. ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0. ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0. ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination

9.2. evaluation of emergency case (sepsis and septic shock-C1)

9.3. approach to healthy individual or patient (fever-C1)

9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)

9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)

9.6. point of care testing (urine strip/dipstick test-C1)

9.7. making preliminary diagnosis or definitive diagnosis decision

9.8. making non-intervention or intervention decision

9.9. practicing non-intervention or intervention

9.10. referral/transport of healthy individual or patient

10.1.***list*** goals and principles of drug use,

10.2.***describe*** effects,

10.3.***explain*** mechanism of action (pharmacodynamics),

10.4.***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,

10.5.***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0. ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0.***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

14.0. ***explain*** hereditary immune system disorders,

15.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

16.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
17.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
18.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
19.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
20.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

HEMATOPOIETIC SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,
11. ***to equip with*** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of hematopoietic system,
2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,
   - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
   - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
   - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination
6.2. evaluation of emergency case
6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***classify*** blood products and blood groups,
8. ***define*** principles of transfusion,
9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. ***list*** principles of cancer chemotherapy,
12. ***explain*** chemotherapy in leukemia and lymphoma,
13. ***list*** phytotherapeutic agents with immunomodulatory effects,
14. ***list*** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.
16. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MD 302 INTRODUCTION TO CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0, 2.0.,3.0. (4.0.-12.0.)	ID	M. Sönmezoğlu	14	6	6	26
1.0, 2.0.,3.0. (4.0.-12.0.)		A.Ç. Büke				
1.0, 2.0.,3.0. (4.0.-12.0.)	MM	İ.Ç. Acuner	7	3	3	13
10.0.	PC	E. Genç	15	4	4	23
10.0.		E.N. Özdamar				
4.0.,5.0.	PT	A. Sav	9	4	4	17
4.0.,5.0.		F. Özkan				
15.0.	BED	E. Vatanoğlu Lutz	9	4	4	17
	HEM	H. A. Özkan	8	3	3	14
6.0.,7.0.,11.0.,12.0.	PH	R. E. Sezer	6	2	2	10
6.0.,7.0.,11.0.,12.0.		H. A.Taşyıkan				
	IMM	G. Y. Demirel	4	2	2	8
14.0.	MG	A. Ç. Kuşkucu	4	2	2	8
8.0.,9.0., 9.1.	PED	S. Kemahlı	4	2	2	8
8.0.,9.0., 9.1.		H. Sarıçoban				
4.0.,5.0.,8.0.	PP	M. Kaçar	2	1	1	4
	PHY	E. Yeşilada	2	1	1	4
16.0.	BS	Ç. Altunok	2	1	1	4
	ONC	O. Kuzhan	2	1	1	4
9.3., 6.0.-9.0.,11.0.,12.0.	FM	G. İzbırak	1	0	0	1
9.2.	EM	M.F. Çelikmen	1	0	0	1
TOTAL			90	36	36	162
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (EMQ)**			
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu/ A.Ç. Büke	2	-	-	2
10.0.	PC	E. Genç	1	-	-	1
	HEM	H.A. Özkan	1	-	-	1
4.0.,5.0.	PT	F. Özkan	1	-	-	1
		TOTAL	5	-	-	5

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****39** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK I / 10 - 14 Sep 2018

	Monday 10-Sep-2018	Tuesday 11-Sep-2018	Wednesday 12-Sep-2018	Thursday 13-Sep-2018	Friday 14-Sep-2018
09.00- 09.50	**Introduction to Phase III**	**Lecture** Introduction to Anemias in Childhood S. Kemahlı	**Lecture** Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) S. Kemahlı	**Independent Learning**	**Lecture** Semiology-I A.Ç. Büke
10.00- 10.50	**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Lecture** Antimicrobial Agents: Basic Concepts & Principles I İ.Ç. Acuner	**Lecture** Hemophilia and other Coagulopathies in Childhood S. Kemahlı	**Independent Learning**	**Lecture** Semiology-II A.Ç. Büke
11.00- 11.50	**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	**Lecture** Antimicrobial Agents: Basic Concepts & Principles II İ.Ç. Acuner	**Lecture** Vancomycin & Other Cell Wall Synthesis Inhibitors E. Genç	**Independent Learning**	**Lecture** Parasitic Infections I A.Ç. Büke
12.00- 12.50	**Lecture** Laboratory Diagnosis of Infectious Diseases I İ.Ç. Acuner	**Lecture** Introduction to Antimicrobial Chemotherapy E. Genç	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections M. Sönmezoğlu	**Independent Learning**	**Lecture** Antimycobacterial Drugs E. Genç
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Laboratory Diagnosis of Infectious Diseases II İ.Ç. Acuner	**Lecture** Laboratory Diagnosis of Infectious Diseases IV Microbiology Lecturer	**Lecture** ß Lactam Antibiotics I E. Genç	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-I R.E. Sezer
15.00- 15.50	**Lecture** Laboratory Diagnosis of Infectious Diseases III İ.Ç. Acuner	**Lecture** Laboratory Diagnosis of Infectious Diseases V Microbiology Lecturer	**Lecture** ß Lactam Antibiotics II E. Genç	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-**II** R.E. Sezer
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I Microbiology Lecturer	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Antimicrobial Agents: Mechanisms of Resistance II Microbiology Lecturer	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK II / 17-21 Sep 2018

	Monday 17-Sep-2018	Tuesday 18-Sep-2018	Wednesday 19-Sep-2018	Thursday 20-Sep-2018	Friday 21-Sep-2018
09.00- 09.50	**Lecture** Prevention and Control of Communicable Diseases I R.E. Sezer	**Lecture** Hospital Infection M. Sönmezoğlu	**Lecture** Aminoglycosides E. Genç	**Independent Learning**	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar
10.00- 10.50	**Lecture** Prevention and Control of Communicable Diseases II R.E. Sezer	**Lecture** Febril Neutropenia M. Sönmezoğlu	**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E. Genç	**Independent Learning**	**Lecture** Pathophysiology of Hematopoietic System Disorders II M. Kaçar
11.00- 11.50	**Lecture** Pathology of Mycobacterial Infections A. Sav	**Lecture** Occupational Health Hazards I A.Ç. Büke	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu	**Independent Learning**	**Lecture** Epidemiology of Communicable Diseases I H.A.Taşyıkan
12.00- 12.50	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Lecture** Occupational Health Hazards II A.Ç. Büke	**Lecture** Infections in Immuncompromised Host M. Sönmezoğlu	**Independent Learning**	**Lecture** Epidemiology of Communicable Diseases II H.A.Taşyıkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Independent Learning**	**Lecture** Parasitic Infections II A.Ç. Büke	**Independent Learning**	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu
15.00- 15.50	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Independent Learning**	**Lecture** Vaccines A.Ç. Büke	**Independent Learning**	**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Tuberculosis & Other Mycobacterial Infections I A.Ç. Büke	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Tuberculosis & Other Mycobacterial Infections II A.Ç. Büke	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK III / 24-28 Sep 2018

	Monday 24-Sep-2018	Tuesday 25-Sep-2018	Wednesday 26-Sep-2018	Thursday 27-Sep-2018	Friday 28-Sep-2018
09.00- 09.50	**Independent Learning**	**Lecture** Non/Hodgkin's Lymphoma I F. Özkan	**Lecture** Hodgkin's Lymphoma F. Özkan	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Independent Learning**	**Lecture** Non/Hodgkin's Lymphoma II F. Özkan	**Lecture** Pathology of Myeloproliferative Diseases-I F. Özkan	**Independent Learning**	**Lecture** Antianemic Drugs E. Genç
11.00- 11.50	**Lecture** Pathology of Bone Marrow-1 F. Özkan	**Lecture** Hematostatic Drugs and Hematostatic Blood Products I E. Genç	**Lecture** Pathology of Myeloproliferative Diseases II F. Özkan	**Independent Learning**	**Lecture** Anthelminthic Drugs E. Genç
12.00- 12.50	**Lecture** Pathology of Bone Marrow-2 F. Özkan	**Lecture** Hematostatic Drugs and Hematostatic Blood Products II E. Genç	**Lecture** Congenital Immunodeficiency Disease H. Sarıçoban	**Independent Learning**	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Lecture** Pathology of Viral Infections I A. Sav	**Lecture** Lymphoreactive Disease F. Özkan
15.00- 15.50	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	GROUP A / GRPUP B IL / GROUP C IL / GROUP D IL	GROUP A IL / GRPUP B IL / GROUP C / GROUP D IL	**Lecture** Pathology of Viral Infections II A. Sav	**Lecture** Pathology of Spleen F. Özkan
16.00- 16.50	**Independent Learning**	GROUP A IL / GRPUP B / GROUP C IL / GROUP D IL	GROUP A IL / GRPUP B IL / GROUP C IL / GROUP D	**Lecture** Investigation of a Disease Epidemic I H.A.Taşyıkan	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Investigation of a Disease Epidemic II H.A.Taşyıkan	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK IV / 1-5 Oct 2018

	Monday 1-Oct-2018	Tuesday 2-Oct-2018	Wednesday 3-Oct-2018	Thursday 4-Oct-2018	Friday 5-Oct-2018
09.00- 09.50	**Lecture** Introduction to the Course I E. Vatanoğlu Lutz	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Introduction to the Course II E. Vatanoğlu Lutz	**ICP-CSL** (Suturing technique) M. F. Çelikmen	**ICP-CSL** (Suturing technique) M. Yazıcıoğlu / C. Şimşek	**ICP-CSL** (Suturing technique) V. Öztürk	**ICP-CSL** (Suturing technique) P. Türe
11.00- 11.50	**Lecture** Physician-Patient Relationship E. Vatanoğlu Lutz	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C Small Group Study** Scientific Project / **Group D ICP**	**Group A Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** Scientific Project
12.00- 12.50	**Lecture** Confidentiality and Truthfulness E. Vatanoğlu Lutz				
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Immunomodulators Pharmacology Lecturer	**Lecture** Beneficence and Non-Maleficence E. Vatanoğlu Lutz	**Independent Learning**	**Lecture** Transhumanisms and Ethics E. Vatanoğlu Lutz	**Lecture** Bioethics E. Vatanoğlu Lutz
15.00- 15.50	**Microbiology Laboratory** (Diagnostic tests of respiratory specimens) Microbiology Instructors	**Lecture** Transplantation E. Vatanoğlu Lutz	**Independent Learning**	**Lecture** Ethics of the Future/Future of Ethics E. Vatanoğlu Lutz	**Lecture** Responsible Biomedical Research E. Vatanoğlu Lutz
16.00- 16.50	GROUP A / GROUP B IL / GROUP C IL / GROUP D IL	**Lecture** Principles of Autonomy and Informed Consent E. Vatanoğlu Lutz	**Independent Learning**	**Lecture** Genetics of Oncology I A.Ç. Kuşkucu	**Lecture** Ethics of Publication E. Vatanoğlu Lutz
17.00-17.50	GROUP A IL / GROUP B / GROUP C IL / GROUP D IL	**Lecture** Justice in Medicine E. Vatanoğlu Lutz	**Independent Learning**	**Lecture** Genetics of Oncology II A.Ç. Kuşkucu	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK V / 8-12 Oct 2018

	Monday 8-Oct-2018	Tuesday 9-Oct-2018	Wednesday 10-Oct-2018	Thursday 11-Oct-2018	Friday 12-Oct-2018
09.00- 09.50	**Case Discussions** Pathology Tissue Response to Infections A. Sav	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Introduction to Clinical Oncology I O. Kuzhan	**Independent Learning**	**Lecture** Blood Components and Transfusion Indications M. Sönmezoğlu
10.00- 10.50	**Case Discussions** General Rewiev of Pathology of Infections Disease A. Sav	**Group A IL** / **Group B IL** / **Group C Small Group Study** Scientific Project / **Group D ICP**	**Lecture** Introduction to Clinical Oncology II O. Kuzhan	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Blood Groups M. Sönmezoğlu
11.00- 11.50	**Microbiology Laboratory** (Diagnostic tests of respiratory specimens) Microbiology Instructors **Group A IL** / **Group B IL** / **Group C** / **Group D IL**		**Lecture** Treatment Approaches of Cancer O. Kuzhan	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Lecture** Antifungal Drugs Pharmacology Lecturer
12.00- 12.50	**Group C IL** / **Group D**	**Lecture** Laboratory Diagnosis of Infectious Diseases VI (Advancements in Diagnostic Microbiology) İ. Ç. Acuner	**Lecture** Phytotherapy I E. Yeşilada		**Lecture** Antiseptics and Disinfectants Pharmacology Lecturer
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Antiprotozoal Drugs Pharmacology Lecturer	**Lecture** Macrolides Pharmacology Lecturer	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Independent Learning**
15.00- 15.50	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** Scientific Project	**Independent Learning**	**Lecture** Antiviral Drugs Pharmacology Lecturer	**Group A Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Independent Learning**
16.00- 16.50		**Independent Learning**	**Independent Learning**		**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VI / 15-19 Oct 2018

	Monday 15-Oct-2018	Tuesday 16-Oct-2018	Wednesday 17-Oct-2018	Thursday 18-Oct-2018	Friday 19-Oct-2018
09.00- 09.50	**Lecture** Phytotherapy II E. Yeşilada	**Lecture** Quantitative and Qualitative Platelet Disorders A. Özkan	**Lecture** Planning Medical Studies I Ç. Altunok	**Lecture** Introduction to Scientific Projects G. Yanıkkaya Demirel	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel
10.00- 10.50	**Lecture** Phytotherapy III E. Yeşilada	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A. Özkan	**Lecture** Planning Medical Studies II Ç. Altunok	**Lecture** Scientific Projects - III: Project Writing G. Yanıkkaya Demirel	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel
11.00- 11.50	**Lecture** Myeloproliferative Diseases A. Özkan	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Lecture** Research Design Ç. Altunok	**Lecture** Lymphoma A. Özkan	**Lecture** Pharmacological Basis of Cancer Therapy I Pharmacology Lecturer
12.00- 12.50	**Lecture** Chronic Leukemia A. Özkan	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Lecture** Approach to the Pediatric Patient with Fever P. Saf	**Lecture** Acute Leukemias A. Özkan	**Lecture** Pharmacological Basis of Cancer Therapy II Pharmacology Lecturer
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Lenforeticular Infections I A.Ç. Büke	**Lecture** Plasma Cell Dyscrasias A. Özkan	**Lecture** Antimalarial Drugs Pharmacology Lecturer	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen	**Multidisciplinary Case Discussion Panel**
15.00- 15.50	**Lecture** Lenforeticular Infections II A.Ç. Büke	**Lecture** Hypercoagulability A. Özkan	**Lecture** Quinolones Pharmacology Lecturer	**Independent Learning**	**Multidisciplinary Case Discussion Panel**
16.00- 16.50	**Lecture** Aplastic and Hypoplastic Anemias A. Özkan	**Lecture** Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias A. Özkan	**Independent Learning**	**Independent Learning**	**Independent Learning**
17.00-17.50	**Lecture** Nutritional Anemias A. Özkan	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VII / 22-26 Oct 2018

<table>
<tr><th></th><th>Monday
22-Oct-2018</th><th>Tuesday
23-Oct-2018</th><th>Wednesday
24-Oct-2018</th><th>Thursday
25-Oct-2018</th><th>Friday
26-Oct-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td rowspan="2">LUNCH BREAK</td></tr>
<tr><td>12.50 – 14.00</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Program Evaluation Session
Committee I
Coordination Committee Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>